Cardiovascular (CV) events are associated with an increased risk of kidney disease progression.1 However, little is known about the trajectory of kidney function change after a CV event, particularly in people treated with contemporary kidney-protective medications such as sodium–glucose cotransporter 2 (SGLT2) inhibitors. We performed a post-hoc analysis using data from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular